MDxHealth SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MDxHealth SA And Ghent University Announces Results For Genome-Wide DNA Methylation Profiling Tools
MDxHealth SA announced the results from a epigenetic next generation sequencing based study that establishes a sensitive and cost-effective industry standard for genome-wide DNA methylation profiling. The results were published in the March 15 PLOS One Volume 8, Issue 3 (e59068). This study is an early result of the NXTGNT Center in Pharmaco (Epi)genomics, a joint collaboration between MDxHealth and the Ghent University announced in November 2012. Methyl Binding Domain (MBD)-based sequencing is the cost-effective method for genome-wide identification of DNA methylation. Five commercially available kits for MBD enrichment, combined with Illumina-based next generation sequencing, were evaluated using inherent sequence data characteristics and importantly, external validation data. Overall, the results obtained confirmed the need for control as the scientists found consistent large-scale differences in yield, sensitivity and specificity between the various kits.
Latest Developments for MDxHealth SA
- Trial results for MDxHealth's Bevacizumab published in New England Journal of Medicine
- MDxHealth's ConfirmMDx Genes identify aggressive prostate cancer
- MDxHealth SA Announces Positive Results of DOCUMENT Clinical Validation Trial of Its ConfirmMDx for Prostate Cancer Test
- MDxHealth SA's Prostate Cancer Test Approved by New York State Department of Health
- Share this
- Digg this